"description","rationale","instanceType","name","uuid:ID","label","id"
"The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign","Study Design 1","e2cd9e48-e1f4-45c9-b063-e21ad438fc19","","StudyDesign_1"
